Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct;9(10):704-16.
doi: 10.1038/nri2635.

Engineering lymphocyte subsets: tools, trials and tribulations

Carl H June  1 , Bruce R Blazar, James L Riley
Affiliations
Review

Engineering lymphocyte subsets: tools, trials and tribulations

Carl H June et al. Nat Rev Immunol. 2009 Oct.

Abstract

Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cell culture approaches for adoptive transfer of lymphocyte subsets
Culture conditions required for distinct lymphocyte subsets vary, depending on the activation and co-stimulatory requirements. a | Cytotoxic T lymphocytes (CTLs) express αβ T cell receptors (TCRs) and are stimulated by antigen-presenting cells (APCs) that express MHC class I molecules. CTLs require 4-1BB ligand (4-1BBL; also known as CD137L) stimulation for clonal expansion and have been expanded in vitro by the addition of feeder cells or artificial APCs that express the co-stimulatory ligands–. b | CD4+ T cells are stimulated by APCs that express peptide-loaded MHC class II complexes. The main co-stimulatory molecule expressed by CD4+ T cells is CD28, which binds to CD80 or CD86 expressed on APCs. Effector CD4+ T cells can be stimulated by artificial APCs (aAPCs) or beads that bear CD3-specific antibody in the presence of various cytokines. Regulatory CD4+ T (TReg) cells require culturing in interleukin-2 (IL-2), and the addition of several reagents to the culture may enhance the suppressive functions of ex vivo expanded TReg cells. c| Cells expressing γδ TCRs, such as the Vγ9Vδ2 TCR expressed by T cells in the blood, are stimulated by APCs that present exogenous isopentenyl pyrophosphate (IPP) or other endogenous ligands stimulated by aminobisphosphonates such as zoledronate,. d| CD1d-restricted Vα24Jα 18+ invaria1nt natural killer T (iNKT) cells are stimulated by α-galactosylceramide (α-GalCer) or the 6B11 clonotype-specific monoclonal antibody. FcR, Fc receptor; HDAC, histone deacetylase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Weiden PL, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073. This was the first study to indicate the potent antitumour effects of human T cells. - PubMed
    1. Rosenberg SA, et al. Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–578. This was the first human gene transfer study. - PubMed
    1. Uchida N, Cone RD, Freeman GJ, Mulligan RC, Cantor H. High efficiency gene transfer into murine T cell clones using a retroviral vector. J Immunol. 1986;136:1876–1879. - PubMed
    1. Naldini L, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267. - PubMed
    1. Amado RG, Chen IS. Lentiviral vectors — the promise of gene therapy within reach? Science. 1999;285:674–676. - PubMed

Publication types

Grants and funding